Submission to the Government of Canada on its Consultation on a National Strategy for High-Cost Drugs for Rare Diseases

The Canadian Life and Health Insurance Association (CLHIA) provided the consolidated view on behalf of its member companies to the Government of Canada on its consultation on a national strategy for high-cost drugs for rare diseases. The submission provides comments on how to address key issues in the government’s discussion paper and presents risk and cost sharing approaches that include private payers.

Submission to the National Strategy for High Cost Drugs for Rare Diseases.pdf